ELPEN Pharmaceutical Co., Inc.
🇬🇷Greece
- Country
- 🇬🇷Greece
- Ownership
- Private
- Established
- 1965-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.elpen.gr
Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Not yet recruiting
- Conditions
- Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06949956
Real World Study in Greek Patients With BPH for Disease Control and QoL Under FDC Treatment With Solifenacin/Tamsulosin.
Recruiting
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT06528613
- Locations
- 🇬🇷
Second Department of Urology, Sismanoglio Hospital, Athens, Greece., Athens, Greece
🇬🇷Department of Urology, Venizelio General Ηospital, Heraklion, Greece
🇬🇷Department of Urology, General Hospital of Messinia, Kalamata, Greece
Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR).
Completed
- Conditions
- Papillomavirus Infections
- Interventions
- Device: Papilocare vaginal gel
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT06399341
- Locations
- 🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷University General Hospital of Larissa, Larissa, Greece
🇬🇷University General Hospital of Patra, Patra, Greece
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Not yet recruiting
- Conditions
- COPD
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06170125
TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.
Recruiting
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06117722
- Locations
- 🇬🇷
ATTIKON University Hospital, Athens, Attica, Greece
Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler
Not Applicable
Completed
- Conditions
- Asthma
- Interventions
- Device: RP - TA
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05459194
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.
Recruiting
- Conditions
- CopdCOPD Exacerbation
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 750
- Registration Number
- NCT05426915
- Locations
- 🇬🇷
Sotiria Hospital, Athens, Attica, Greece
Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease.
Recruiting
- Conditions
- Diffuse Cutaneous Systemic SclerosisReynold SyndromeSclerodermaDigital UlcerAutoimmune Diseases
- First Posted Date
- 2021-12-23
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT05168215
- Locations
- 🇬🇷
Laikon Hospital of Athens, Athens, Greece
AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.
Completed
- Conditions
- Asthma
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 1037
- Registration Number
- NCT04835961
- Locations
- 🇬🇷
Sotiria Hospital, Athens, Greece
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
Completed
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 1296
- Registration Number
- NCT04831476
- Locations
- 🇬🇷
Laikon Hospital of Athens, Athens, Greece